ICE Bioscience

Excited to share that we’re expanding our Antibody-Drug Conjugate (ADC) services to offer even more comprehensive solutions for our partners! 👉https://lnkd.in/gEWvG7J4 From innovative payload screening and in-depth bystander effect assays to advanced in vivo models, we’re here to support every step of your ADC journey. With our extensive experience and tailored approach, we help turn groundbreaking science into real-world therapies. Let's innovate together and take ADC discovery to the next level! #ADC #Biotech #payload #DMPK #bystandereffect #DrugDevelopment #invivo #invitro

PCSK9 inhibitors are unlocking new treatment possibilities across cardiovascular disease, diabetes complications, and neurodegenerative disorders by enhancing cholesterol clearance and LDLR preservation. Small-molecule PCSK9 inhibitors, offering oral bioavailability, cost-effectiveness, and stability, represent a promising alternative to antibodies. Key industry players like Merck (with MK-0616 in Phase III trials), AstraZeneca (with AZD0780 in Phase II trials) and LIB Therapeutics (with Lerodalcibep in Phase III trials) are actively leading the charge in this innovative space. We’re advancing PCSK9 inhibitors discovery with our specialized assay platforms, offering: 🔸 PCSK9-LDLR HTRF Assay for efficient and precise small molecule PCSK9 inhibitor high-throughput screening. 🔸 PCSK9 ELISA for downstream validation of robust quantification. 🔸 PCSK9-HepG2 Cell-Based Assay is a multi-dimensional analysis platform based on liver cancer cell lines, for high-throughput screening and functional validation. With these innovative techniques, ICE Bioscience enable researchers to accelerate PCSK9-related therapies development and driver significant solutions. #PCSK9 #InhibitorsScreening #HTRF #ELISA #CellBaseAssay #HepG2 #LDLR #DrugDiscovery #HTS #Treatment

ICE Bioscience is gearing up for the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting in Houston, and we can’t wait to connect with all of you there! If you’re planning to attend, come swing by our booth at #1030. Let’s chat about all things immunotherapy—especially our latest services in biomarker discovery, ADC (Antibody-Drug Conjugate) development, and advanced immunology solutions. See you in Houston! 🚀 #SITC2024 #immunotherapy

Hello Barcelona! 👋 We’ve wrapped up Day 1 of the 36th EORTC-NCI-AACR Symposium and it’s been nothing short of amazing. The ICE Bioscience team is here to exchange insights and dive into deep discussions on new molecular targets and emerging therapies. Swing by our booth # 13 for a chat! Excited to see what the next two days have in store. Let’s keep pushing the boundaries of discovery! #ENASymp2024 #DrugScreening #CancerResearch #EORTC #NCI #AACR #MolecularTherapeutics

As researchers continue to uncover the role of ACVR2B in muscle growth and metabolic regulation, innovative approaches to targeting this pathway are driving new therapeutic possibilities. To advance ACVR2B-targeted drug discovery, our team has developed specialized assays to evaluate therapeutic candidates. ✅ HTRF-based Activity Assays: Measure kinase-mediated phosphorylation using robust ULight-Eu technology. ✅ HTRF-based Binding Assays: Assess compound-receptor interactions through competitive binding techniques. ✅ CAGA-luciferase Reporter Gene Assays: Quantify Activin A-induced Smad2/3 activity for a comprehensive readout of pathway modulation. With our selectivity biochemical assays spanning ACVR2A, ALK1-ALK7, TGFβR2, and BMPR2, we also provide insights into off-target effects and selectivity profiles, empowering our partners to develop more targeted and effective therapeutics. #ACVR2B #ActRIIB #DrugDiscovery #TGFb #HTRF #FRET #Reporterassay

If you're at American Association of Pharmaceutical Scientists (AAPS) | @aapscomms PharmSci 360, don’t miss out on the chance to meet Dr. Xiao Guo and Dr. Fujun Zhang as they present three exciting posters. They are ready to chat about the latest developments in our solutions. We’d love for you to swing by, say hello, and dive into some great science with us. ☑️ T1030-04-21: A PARPi Screening Cascade to Facilitate Novel Drug Discovery ☑️ M1030-04-19: Integrated Screening Platform of PDE for Lung Fibrosis Drug Discovery ☑️ M1230-04-24: Screening of CDK Inhibitors in Breast Cancer #AAPSPharmSci360 #DrugDiscovery #PosterPresentation #Networking 

We will be presenting six posters at the 36th EORTC-NCI-AACR Symposium (ENA 2024) in Barcelona! Join us on Friday, 25 October 2024, at the Poster Session: "Drug Screening", where we’ll be showcasing the latest solutions in drug screening and cancer therapeutics. We look forward to connecting with you to discuss the future of cancer drug development! #ENASymp2024 #DrugScreening #CancerResearch #MolecularTherapeutics #drugdiscovery #EORTC #AACR

ICE Bioscience will be showcasing three posters at the AAPS PharmSci 360 2024, taking place from October 20-23 in Salt Lake City, UT. Our posters focus on innovative drug discovery and screening solutions, and will be presented by Dr. Fujun Zhang and Dr. Xiao Guo: ☑️ T1030-04-21: A PARPi Screening Cascade to Facilitate Novel Drug Discovery ☑️ M1030-04-19: Integrated Screening Platform of PDE for Lung Fibrosis Drug Discovery ☑️ M1230-04-24: Screening of CDK Inhibitors in Breast Cancer Looking forward to engaging with fellow experts and industry leaders! #AAPSPharmSci360 #DrugDiscovery #PharmaceuticalScience #OncologyResearch #LungFibrosis #PARPInhibitors #CDKInhibitors #ScientificPosters #AAPS

We will be exhibiting at the 36th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics, taking place from October 23-25, 2024, at the CCIB in Barcelona, Spain. We invite all attendees to stop by Booth 13 to learn more about our cancer research solutions. Don't miss this opportunity to network, discover new insights, and be part of the conversation shaping the future of cancer therapeutics. We look forward to meeting you in Barcelona! #ENA2024 #AACR #EORTCNCIAACR #CANCER #THERAPEUTICS #TARGETS

Kymera Therapeutics is making significant advancements with its IRAK4 degrader, KT-474, which is currently in Phase II clinical trials. The drug is being developed for the treatment of hidradenitis suppurativa and atopic dermatitis. In earlier Phase 1 trials, KT-474 demonstrated significant IRAK4 protein degradation - achieving up to 95% degradation in healthy volunteers, indicating its strong potential in treating complex inflammatory diseases. ICE Bioscience is at the forefront of supporting IRAK4-targeted therapeutic development. Our latest Application Note covers comprehensive assays for characterizing IRAK4 inhibitors and degraders. Learn more about how our capabilities can help accelerate your IRAK4 research! 👉 https://lnkd.in/gaczDuPr #IRAK4 #DrugDevelopment #Immunology #PROTAC #degraders #InnateImmunity #Inflammation #Biotech #Innovation